Last $7.12 USD
Change Today -0.09 / -1.25%
Volume 29.2K
AQXP On Other Exchanges
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

aquinox pharmaceuticals inc (AQXP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/13/14 - $14.35
52 Week Low
08/26/14 - $6.22
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

aquinox pharmaceuticals inc (AQXP) Related Businessweek News

No Related Businessweek News Found

aquinox pharmaceuticals inc (AQXP) Details

Aquinox Pharmaceuticals Inc., a clinical stage pharmaceutical company, discovers and develops oral drug candidates for the treatment of inflammatory diseases and cancer. The company primarily focuses on anti-inflammatory product candidates targeting SHIP1, a key regulator of a cellular signaling pathway in immune cells. Its principal product candidate is AQX-1125, a SHIP1 activator, which is in Phase II clinical trials for chronic obstructive pulmonary disease and bladder pain syndrome/interstitial cystitis. The company was formerly known as 6175813 Canada Inc. and changed its name to Aquinox Pharmaceuticals Inc. in March 2006. Aquinox Pharmaceuticals Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

19 Employees
Last Reported Date: 08/11/14
Founded in 2003

aquinox pharmaceuticals inc (AQXP) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $420.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $183.3K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $270.2K
Compensation as of Fiscal Year 2013.

aquinox pharmaceuticals inc (AQXP) Key Developments

Aquinox Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Aquinox Pharmaceuticals Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company net loss before income taxes of $5,424,759 against $811,502 a year ago. Net loss was $5,424,759 against $811,502 a year ago. The increase in net loss was primarily due to the ongoing advancement of AQX-1125 through the FLAGSHIP and LEADERSHIP trials, and costs associated with operating as a public company. For the six months, the company reported net loss before income taxes of $9,652,437 against $1,821,769 a year ago. Net loss was $9,652,437 against $1,821,769 a year ago.

Aquinox Pharmaceuticals Inc. to Report Q2, 2014 Results on Aug 11, 2014

Aquinox Pharmaceuticals Inc. announced that they will report Q2, 2014 results After-Market on Aug 11, 2014

Aquinox Pharmaceuticals Inc., Q2 2014 Earnings Call, Aug 11, 2014

Aquinox Pharmaceuticals Inc., Q2 2014 Earnings Call, Aug 11, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AQXP:US $7.12 USD -0.09

AQXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AQXP.
View Industry Companies

Industry Analysis


Industry Average

Valuation AQXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AQUINOX PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at